0.35Open0.15Pre Close1 Volume5 Open Interest0.50Strike Price35.00Turnover364.62%IV17.24%PremiumDec 20, 2024Expiry Date0.23Intrinsic Value100Multiplier25DDays to Expiry0.12Extrinsic Value100Contract SizeAmericanOptions Type0.8059Delta0.3984Gamma2.07Leverage Ratio-0.0038Theta0.0002Rho1.67Eff Leverage0.0005Vega
BriaCell Therapeutics Stock Discussion
2 mins ago
Briacell Announces First Patient Dosed With Bria-Ots™ in Metastatic Breast Cancer Study
1 MINUTE AGO, 7:50 AM EST
VIA GLOBENEWSWIRE
BriaCell's clinical candidates for next generation breast cancer (Bria-BRES+™) and prostate cancer (Bria-PROS+™) generate robust anti-cancer activity in preclinical models
Novel therapy activates both innate and adaptive immune systems
Proof of concept Phase 1/2 Study of Bria-BRES™ in met...
3 MINUTES AGO, 7:50 AM EDT
VIA GLOBENEWSWIRE
55% of BriaCell patients1 remained alive one year since enrollment in BriaCell's Phase 2 study, markedly exceeding the survival rate of current standard of care for similar patients
Multiple outperforming patients with overall survival of over 2 years
Survival benefit observed even in heavily pre-treated patients w...
BriaCell Reports Outperforming Metastatic Breast Cancer Patients and Standard-Beating Survival Data
▪️55% of BriaCell patients1 remained alive one year since enrollment in BriaCell's Phase 2 study, markedly exceeding the survival rate of current standard of care for similar patients
▪️Multiple outperforming patients with overall survival of over 2 years
▪️Survival benefit observed even in heavily pre-treated patients who failed treatment with checkpoint inhib...
5 MINUTES AGO, 7:50 AM EDT
VIA GLOBENEWSWIRE
35 sites active and enrolling in pivotal Phase 3 study of Bria-IMT™ combination with immune check point inhibitor in metastatic breast cancer (MBC)
Primary endpoint is overall survival (OS) with Bria-IMT™ regimen plus Check Point Inhibitor (CPI) vs treatment of physician's choice
Interim data analysis planned at 144 eve...
No comment yet